Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer
Smith, Kate M
Waddell, Ian D
Ogilvie, Donald J
James, Dominic I
Jordan, Allan M
AffiliationDepartment of Surgery, Thomas Jefferson University
MetadataShow full item record
AbstractPatients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than one year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (ELAVL1). Here, we evaluated PARG as a target in PDAC models using both genetic silencing of PARG and established small molecule PARG inhibitors, PDDX-001/004 (PARGi). Homologous repair-deficient cells compared to homologous repair-proficient cells were more sensitive to PARG inhibitors in vitro. In vivo, silencing of PARG significantly decreased tumor growth. PARGi synergized with DNA damaging agents (i.e., oxaliplatin and 5-FU), but not with PARP inhibitor therapy. Mechanistically, combined PARGi and oxaliplatin treatment led to persistence of detrimental PARylation, increased expression of cleaved caspase 3 and increased -H2AX foci. In summary, these data validate PARG as a relevant target in PDAC and establish current therapies that synergize with PARGi.
CitationJain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Res. 2019 Jul 4.
- Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.
- Authors: Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR
- Issue date: 2017 Sep 15
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
- Authors: Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ
- Issue date: 2019 Jun
- Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
- Authors: Fathers C, Drayton RM, Solovieva S, Bryant HE
- Issue date: 2012 Mar 1
- Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint.
- Authors: Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F
- Issue date: 2013 Nov 29
- Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death.
- Authors: Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A, Laverty D, Walker BL, Pourfarjam Y, Warden LS, Babu Chinnam N, Moiani D, Stegeman RA, Chen MK, Hung MC, Nagel ZD, Ellenberger T, Kim IK, Jones DE, Ahmed Z, Tainer JA
- Issue date: 2019 Dec 11